NEW HOPE, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact ...

With FDA approval of an investigational device exemption, J&J’s soft tissue robot moves a step closer to challenging ...

Johnson & Johnson MedTech has received a go-ahead from the FDA to begin human clinical trials of its Ottava surgical robot, ...

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, "Orchestra BioMed" or the "Company"), a biomedical innovation company accelerating high-impact technologies ...

Boston Scientific expects to complete enrollment in the coming months in the study comparing pulsed field ablation to ...

The company now has 87 hospitals ... LockeT in patients that require large-bore venous access such as those used with the Micra pacemakers from Medtronic, the Watchman devices from Boston Scientific, ...

November 13, 2024--(BUSINESS WIRE)--Lumicell, Inc., a privately held company focused on developing innovative ... at large ...

This growth is primarily driven by the rising prevalence of cardiovascular diseases (CVDs) worldwide, alongside continuous ...

Hopefully if I make Euro Cross again it’ll feel a bit better.” Everard is currently on placement at Medtronic in Galway, a ...

Clearside Biomedical, Inc. (CLSD) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.15 per share a year ago. These ...

The global ageing population and growing awareness of the benefits of orthobiologic therapy are driving the size of the global orthobiologics market.